A study on mutual interaction between cytokine induced killer cells and umbilical cord-derived mesenchymal cells: Implication for their in-vivo use

Blood Cells, Molecules, and Diseases

Volumn 49, Issue 3-4, 2012, Pages 159-165

  Chieregato, Katia ^a   Albiero, Elena ^a,b   Castegnaro, Silvia ^a   Bernardi, Martina ^a,b   d'Amore, Emanuele S G ^a   Zanon, Cristina ^a   Madeo, Domenico ^b   Rodeghiero, Francesco ^a,b   Astori, Giuseppe ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b Fondazione Progetto Ematologia   (Italy)

Author keywords

Co culture; Cytokine induced killer (CIK) cells; Cytotoxicity; Mesenchymal stromal cells (MSC); Umbilical cord

Indexed keywords

CYTOKINE;

ARTICLE; CELL INTERACTION; CELL ISOLATION; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KILLER CELL; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; UMBILICAL CORD; UMBILICAL CORD MESENCHYMAL CELL;

BIOLOGICAL MARKERS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINE-INDUCED KILLER CELLS; CYTOKINES; FEMALE; FETAL BLOOD; HUMANS; K562 CELLS; MESENCHYMAL STROMAL CELLS; PREGNANCY; REAL-TIME POLYMERASE CHAIN REACTION; UMBILICAL CORD;

EID: 84865960832     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2012.05.009     Document Type: Article

References (42)

1. Sangiolo D., Mesiano G., Carnevale-Schianca F., Piacibello W., Aglietta M., Cignetti A. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin. Biol. Ther. 2009, 9:831-840.
2. Jiang J.T., Shen Y.P., Wu C.P., Zhu Y.B., Wei W.X., Chen L.J., Zheng X., Sun J., Lu B.F., Zhang X.G. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J. Gastroenterol. 2010, 16:6155-6162.
3. Olioso P., Giancola R., Di Riti M., Contento A., Accorsi P., Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol. Oncol. 2009, 27:130-139.
4. Schmidt-Wolf I.G., Finke S., Trojaneck B., Denkena A., Lefterova P., Schwella N., Heuft H.G., Prange G., Korte M., Takeya M., Dorbic T., Neubauer A., Wittig B., Huhn D. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br. J. Cancer 1999, 81:1009-1016.
5. Weng D.S., Zhou J., Zhou Q.M., Zhao M., Wang Q.J., Huang L.X., Li Y.Q., Chen S.P., Wu P.H., Xia J.C. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J. Immunother. 2008, 31:63-71.
6. Hui D., Qiang L., Jian W., Ti Z., Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig. Liver Dis. 2009, 41:36-41.
7. Shi M., Yao L., Wang F.S., Lei Z.Y., Zhang B., Li W.L., Liu J.C., Tang Z.R., Zhou G.D. Growth inhibition of human hepatocellular carcinoma xenograft in nude mice by combined treatment with human cytokine-induced killer cells and chemotherapy. Zhonghua Zhong Liu Za Zhi 2004, 26:465-468.
8. Jiang J., Xu N., Wu C., Deng H., Lu M., Li M., Xu B., Wu J., Wang R., Xu J., Nilsson-Ehle P. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 2006, 26:2237-2242.
9. Wu C., Jiang J., Shi L., Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 2008, 28:3997-4002.
10. Introna M., Pievani A., Borleri G., Capelli C., Algarotti A., Mico C., Grassi A., Oldani E., Golay J., Rambaldi A. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol. Blood Marrow Transplant. 2010, 16:1603-1607.
11. Laport G.G., Sheehan K., Baker J., Armstrong R., Wong R.M., Lowsky R., Johnston L.J., Shizuru J.A., Miklos D., Arai S., Benjamin J.E., Weng W.K., Negrin R.S. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2011, 17:1679-1687.
12. Leemhuis T., Wells S., Scheffold C., Edinger M., Negrin R.S. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transplant. 2005, 11:181-187.
13. Introna M., Borleri G., Conti E., Franceschetti M., Barbui A.M., Broady R., Dander E., Gaipa G., D'Amico G., Biagi E., Parma M., Pogliani E.M., Spinelli O., Baronciani D., Grassi A., Golay J., Barbui T., Biondi A., Rambaldi A. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007, 92:952-959.
14. Noort W.A., Kruisselbrink A.B., in't Anker P.S., Kruger M., van Bezooijen R.L., de Paus R.A., Heemskerk M.H., Lowik C.W., Falkenburg J.H., Willemze R., Fibbe W.E. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp. Hematol. 2002, 30:870-878.
15. Angelopoulou M., Novelli E., Grove J.E., Rinder H.M., Civin C., Cheng L., Krause D.S. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp. Hematol. 2003, 31:413-420.
16. Kebriaei P., Isola L., Bahceci E., Holland K., Rowley S., McGuirk J., Devetten M., Jansen J., Herzig R., Schuster M., Monroy R., Uberti J. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol. Blood Marrow Transplant. 2009, 15:804-811.
17. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., Marschall H.U., Dlugosz A., Szakos A., Hassan Z., Omazic B., Aschan J., Barkholt L., Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
18. Fang B., Song Y., Liao L., Zhang Y., Zhao R.C. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant. Proc. 2007, 39:3358-3362.
19. Lucchini G., Introna M., Dander E., Rovelli A., Balduzzi A., Bonanomi S., Salvade A., Capelli C., Belotti D., Gaipa G., Perseghin P., Vinci P., Lanino E., Chiusolo P., Orofino M.G., Marktel S., Golay J., Rambaldi A., Biondi A., D'Amico G., Biagi E. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol. Blood Marrow Transplant. 2010, 16:1293-1301.
20. Wexler S.A., Donaldson C., Denning-Kendall P., Rice C., Bradley B., Hows J.M. Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. Br. J. Haematol. 2003, 121:368-374.
21. Wagner W., Bork S., Horn P., Krunic D., Walenda T., Diehlmann A., Benes V., Blake J., Huber F.X., Eckstein V., Boukamp P., Ho A.D. Aging and replicative senescence have related effects on human stem and progenitor cells. PLoS One 2009, 4:e5846.
22. Zuk P.A., Zhu M., Ashjian P., De Ugarte D.A., Huang J.I., Mizuno H., Alfonso Z.C., Fraser J.K., Benhaim P., Hedrick M.H. Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 2002, 13:4279-4295.
23. Bieback K., Kern S., Kluter H., Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004, 22:625-634.
24. Bieback K., Kluter H. Mesenchymal stromal cells from umbilical cord blood. Curr. Stem Cell Res. Ther. 2007, 2:310-323.
25. Capelli C., Gotti E., Morigi M., Rota C., Weng L., Dazzi F., Spinelli O., Cazzaniga G., Trezzi R., Gianatti A., Rambaldi A., Golay J., Introna M. Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy 2011, 13:786-801.
26. Zeddou M., Briquet A., Relic B., Josse C., Malaise M.G., Gothot A., Lechanteur C., Beguin Y. The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. Cell Biol. Int. 2010, 34:693-701.
27. Baron F., Lechanteur C., Willems E., Bruck F., Baudoux E., Seidel L., Vanbellinghen J.F., Hafraoui K., Lejeune M., Gothot A., Fillet G., Beguin Y. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol. Blood Marrow Transplant. 2010, 16:838-847.
28. Chieregato K., Castegnaro S., Madeo D., Astori G., Pegoraro M., Rodeghiero F. Epidermal growth factor, basic fibroblast growth factor and platelet-derived growth factor-bb can substitute for fetal bovine serum and compete with human platelet-rich plasma in the ex vivo expansion of mesenchymal stromal cells derived from adipose tissue. Cytotherapy 2011, 13:933-943.
29. Johnstone B., Hering T.M., Caplan A.I., Goldberg V.M., Yoo J.U. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp. Cell Res. 1998, 238:265-272.
30. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
31. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
32. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
33. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A., Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 2002, 30:42-48.
34. Zhang W., Ge W., Li C., You S., Liao L., Han Q., Deng W., Zhao R.C. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004, 13:263-271.
35. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006, 24:74-85.
36. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
37. Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C., Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008, 111:1327-1333.
38. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., Noel D., Jorgensen C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
39. Ning H., Yang F., Jiang M., Hu L., Feng K., Zhang J., Yu Z., Li B., Xu C., Li Y., Wang J., Hu J., Lou X., Chen H. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008, 22:593-599.
40. Capelli C., Salvade A., Pedrini O., Barbui V., Gotti E., Borleri G., Cabiati B., Belotti D., Perseghin P., Bellavita P., Biondi A., Biagi E., Rambaldi A., Golay J., Introna M. The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. Cytotherapy 2009, 11:403-413.
41. Yamashita A., Krawetz R., Rancourt D.E. Loss of discordant cells during micro-mass differentiation of embryonic stem cells into the chondrocyte lineage. Cell Death Differ. 2009, 16:278-286.
42. Franceschetti M., Pievani A., Borleri G., Vago L., Fleischhauer K., Golay J., Introna M. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp. Hematol. 2009, 37:616-628. (e612).